Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
Background. Immune thrombocytopenia (ITP), or idiopathic thrombocytopenic purpura, is a hematological autoimmune disease characterized by bleeding and an isolated decrease in platelet count <100 × 109 / l. The decision to start treatment for ITP depends on several factors. The ITP treatment s...
Saved in:
Main Authors: | S. G. Zakharov, T. A. Mitina, R. V. Vardanyan, Z. R. Tekeeva, I. N. Kontievskiy, Yu. Yu. Chuksina, A. V. Zakharova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2023-09-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/837 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01) -
Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01) -
Immune thrombocytopenia: literature review
by: S. G. Zakharov
Published: (2024-09-01) -
Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01) -
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01)